晚期胃癌化疗及分子靶向治疗研究进展  

Advancement in chemotherapy and molecular targeted therapy of advanced gastric cancers

作　　者：王芳[1] 柳江[1] 罗健[2] 

机构地区：[1]新疆维吾尔自治区人民医院肿瘤科,乌鲁木齐830001 [2]中国医学科学院北京协和医学院肿瘤医院,国家癌症中心肿瘤内科,北京100021

出　　处：《中国医师杂志》2016年第1期18-21,25,共5页Journal of Chinese Physician

摘　　要：目前化疗仍然是晚期胃癌的主要治疗手段,但尚无标准方案.与最佳支持治疗相比,化疗可延长患者中位生存期,提高其生存质量.近年来,随着各种新型抗癌药物的出现,化疗方案不断演进,晚期胃癌的治疗有效率和生存期得到进一步提高.同时,随着胃癌分子生物学研究的不断深入,针对人表皮生长因子受体2（HER-2）、表皮生长因子受体（EGFR）、血管内皮生长因子（VEGF）的分子靶向治疗成为胃癌综合治疗的热点.化疗联合分子靶向治疗在晚期胃癌中显示出良好的治疗效果及前景,但仍需在临床研究和实践中进一步调整和优化.本文将结合最新文献,对晚期胃癌的化疗及分子靶向治疗进行综述.Chemotherapy is still the main treatment in advanced gastric cancer by now,but no standard approach has been adopted.Chemotherapy can prolong median overall survival and improve quality of life compared to the best supportive care alone.Recent years,with the appearance of various new agents,chemotherapy remains continuous improvement.As a result,response rate and overall survival of advanced gastric cancers were further improved.Meanwhile,with a greater understanding of the molecular biology of gastric cancer,molecular biological targeted therapies that target human epidermal growth factor receptor 2 （HER-2）,endothelial growth factor receptor （EGFR） and vascular endothelial growth factor （VEGF） become the focus of the comprehensive treatment.Chemotherapy combined targeted therapy have shown great benefit and perspective in treatment of advanced gastric cancer,but their usage should be further modified and optimized in clinical trials and practices.

关 键 词：胃肿瘤/治疗 综述 

分 类 号：R735.2[医药卫生—肿瘤]